VALN · Valneva SE

Track VALN — free

$6.66 -0.03 (-0.45%) At close · Sep 11

Rebalance outlook locked

Market Cap

$625.36M

94.82M

Up next

Next earnings call

Nov 13, 2026 Est · unconfirmed · in 9 wks

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-26.2%

Trailing year

Short interest

0.2%

Latest settlement · 4.5 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 15, 2026

Emergent BioSolutions: leveraged biodefense name trades like a Narcan story while international MCM mix hits 37%

A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −9%

below

Price vs 50-day avg +15%

above

RSI (14) 56

neutral

MACD trend Negative

52-week position 25%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +18%

trailing

6-month return −35%

trailing

YTD return −24%

this year

Relative strength −53%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $6 › 200d $7 — 200d above 50d

Institutional flow Distributing

-5% holders QoQ · +6 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

0.20% of float · ▲ +20.9% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

20 holders — mid 3-yr range

Squeeze score 50

elevated · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 69%

annualized · 1-yr

Max drawdown −61%

past year

ATR 4.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−9% Bearish

Price vs 50-day avg

+15% Bullish

RSI (14)

56 Neutral

MACD trend

Negative Bearish

52-week position

25% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $6 › 200d $7 — 200d above 50d

Institutional flow Distributing

-5% holders QoQ · +6 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

0.20% of float · ▲ +20.9% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

20 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $5 Now $7 · 25% Range high $12

vs 200-day avg -9% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
VALN Valneva SE this stock	$625.36M	-24.5%	—	—	0.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 4.0%
Net QoQ: -127.6K sh
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

194.1K

Days to cover: 4.5d
Change: +33.6K sh

View

Short Volume

Short vol %

88%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

2.8K

Value: $14.3K
As of: Aug 7, 2026

View

Off-Exchange

Off-exchange %

30.7%

Week of: Aug 3, 2026

Off-exch Lit

View

Filings

SEC Filings

Latest

6-K

Filed: Aug 14, 2026
This year: 20

View

Earnings & Events

Earnings Calls Upcoming

Next call

Nov 16, 2026

Last call: Aug 13, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
VALN	-5.7%	+17.9%	-35.5%	+5.7%	-24.5%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-4.5%	+19.6%	-53.3%	+6.1%	-36.6%

Key facts CIK 1836564 CUSIP 92025Y103 13F (30d) 12 filings 12 filers Visit website Investor relations

VALN · Valneva SE

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Equibles Rating

Technicals

Versus peers

At a glance

Performance